<DOC>
	<DOCNO>NCT02702648</DOCNO>
	<brief_summary>The primary purpose first-in-man study investigate whether new drug neurological disorder safe well-tolerated administer orally healthy adult</brief_summary>
	<brief_title>First-in-man Study Single Multiple Ascending Doses New Drug Neurological Disorders</brief_title>
	<detailed_description />
	<mesh_term>Nervous System Diseases</mesh_term>
	<criteria>Key inclusion Criteria : Signed informed consent Healthy basis physical examination,12lead electrocardiogram laboratory test Males female nonchildbearing potential , age 18 60 year ( inclusive ) Women must negative serum pregnancy test Screening negative urine pregnancy test predose Day 1 Body mass index ( BMI ) 18.0 29.9 kg/m2 ( inclusive ) Systolic blood pressure ( SBP ) , diastolic blood pressure ( DBP ) pulse rate ( PR ) 90140 mmHg , 5090 mmHg 5090 bpm ( inclusive ) , respectively Key exclusion Criteria : History clinical evidence disease and/or existence surgical medical condition might interfere absorption , distribution , metabolism excretion study treatment Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction Any circumstance condition , , opinion Investigator , may affect full participation study compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>healthy subject</keyword>
	<keyword>first-in-man</keyword>
	<keyword>safety</keyword>
</DOC>